VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice

International Immunopharmacology

Volumn 9, Issue 1, 2009, Pages 70-79

  Ou, Xue Mei ^a   Li, Wan Cheng ^a   Liu, Dai Shun ^a   Li, Yan Ping ^a   Wen, Fu Qiang ^a   Feng, Yu Lin ^a   Zhang, Shang Fu ^a   Huang, Xiang Yang ^a   Wang, Tao ^a   Wang, Ke ^a   Wang, Xun ^a   Chen, Lei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Pulmonary fibrosis; SU5416; VEGF; VEGFR 2(Flk 1)

Indexed keywords

BLEOMYCIN; COLLAGEN; INTERLEUKIN 13; LACTATE DEHYDROGENASE; SEMAXANIB; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; INFLAMMATION; LUNG FIBROSIS; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; FLOW CYTOMETRY; HYDROXYPROLINE; INDOLES; LUNG; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PULMONARY FIBROSIS; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 58149459331     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.10.002     Document Type: Article

References (54)

1. American Thoracic Society and European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161 (2000) 646-664
2. Crouch E. Pathobiology of pulmonary fibrosis. Am J Physiol 259 (1990) L159-L184
3. Beer T.W., Baldwin H.C., Goddard J.R., Gallagher P.J., and Wright D.H. Angiogenesis in pathological and surgical scars. Hum Pathol 29 (1998) 1273-1278
4. Klein S.A., Bond S.J., Gupta S.C., Yacoub O.A., and Anderson G.L. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 82 (1999) 268-274
5. Keane M.P., Belperio J.A., Moore T.A., Moore B.B., Arenberg D.A., Smith R.E., et al. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin- induced pulmonary fibrosis. J Immunol 162 (1999) 5511-5518
6. Burdick M.D., Murray L.A., Keane M.P., Xue Y.Y., Zisman D.A., Belperio J.A., et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 171 (2005) 261-268
7. Fehrenbach H., Kasper M., Haase M., Schuh D., and Müller M. Differential immunolocalization of VEGF in rat and human adult lung, and in experimental rat lung fibrosis: light, fluorescence, and electron microscopy. Anat Rec 254 (1999) 61-73
8. Plate K.H., Breier G., Weich H.A., and Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
9. Rahimi N., Dayanir V., and Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 275 (2000) 16986-16992
10. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99 (1997) 2625-2634
11. Marumo T., Schini-Kerth V.B., and Busse R. Vascular endothelial growth factor activates nuclear factor-κB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 48 (1999) 1131-1137
12. Ashcroft T., Simpson J.M., and Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41 (1988) 467-470
13. Woessner J.F. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 93 (1961) 440-447
14. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147 (1995) 9
15. -CT method. Method 25 (2001) 402-408
16. Keane M.P., Arenberg D.A., Lynch III J.P., Whyte R.I., Iannettoni M.D., Burdick M.D., et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159 (1997) 1437-1443
17. Higashiyama H., Yoshimoto D., Okamoto Y., Kikkawa H., Asano S., and Kinoshita M. Receptor-activated Smad localization in bleomycin-induced pulmonary fibrosis. J Clin Pathol 60 (2007) 283-289
18. Zhao J., Shi W., Wang Y.L., Chen H., Bringas Jr. P., Datto M.B., et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 282 (2002) 585
19. Azuma A., Li Y.J., Abe S., Usuki J., Matsuda K., Henmi S., Miyauchi Y., et al. Interferon-β inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-β and thrombospondin. Am J Respir Cell Mol Biol 32 (2005) 93-98
20. Hamada N., Kuwano K., Yamada M., Hagimoto N., Hiasa K., Egashira K., et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 175 2 (2005) 1224-1231
21. Adamson I.Y., and Bowden D.H. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 77 (1974) 185-197
22. Chandler D.B. Possible mechanisms of bleomycin-induced fibrosis. Clin Chest Med 11 (1990) 21-30
23. Moulton K.S., Melder R.J., Dharnidharka V.R., Hardin-Young J., Jain R.K., and Briscoe D.M. Angiogenesis in the huPBL-SCID model of human transplant rejection. Transplantation 67 12 (1999) 1626-1631
24. Hamada N., Kuwano K., Yamada M., Hagimoto N., Hiasa K., Egashira K., et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 175 (2005) 1224-1231
25. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59 (1999) 99-106
26. Ellis L.M., Takahashi Y., Liu W., and Shaheen R.M. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5 (2000) 11-15
27. Mendel D.B., Schreck R.E., West D.C., Li G., Strawn L.M., Tanciongco S.S., et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6 (2000) 4848-4858
28. Sung S.H., Ziyadeh F.N., Wang A., Pyagay P.E., Kanwar Y.S., and Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 17 (2006) 3093-3104
29. Taraseviciene-Stewart L., Kasahara Y., Alger L., Hirth P., Mc Mahon G., Waltenberger J., et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB 15 (2001) 427
30. Loges S., Tinnefeld H., Metzner A., Jucker M., Butzal M., Bruweleit M., et al. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. Leuk Lymphoma 47 12 (2006) 2601-2609
31. Taraseviciene-Steward L., Kasahara Y., Alger L., Hirth P., McMahon G., Waltenberger J., et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB 15 (2001) 427
32. Li Z.D., Bork J.P., Krueger B., Patsenker E., Schulze-Krebs A., Hahn E.G., et al. VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 334 4 (2005) 1049-1060
33. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79 (1997) 233-269
34. Milojkovic D., Sahu S., Henderson J., Czepulkowski B.H., Salisbury J.R., Bellamy W.T., et al. Immunohistochemical characterisation of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR in chronic myeloid leukaemia (CML) patients treated with imatinib mesylate. Blood 104 (2004) 1999
35. Tsokos M., Pufe T., Paulsen F., Anders S., and Mentlein R. Pulmonary expression of vascular endothelial growth factor in sepsis. Arch Pathol Lab Med 127 3 (2003) 331-335
36. 1 production through a PI3K/Akt signaling pathway. Eur Respir J 31 (2008) 523-531
37. Jeon S.H., Chae B.C., Kim H.A., Seo G.Y., Seo D.W., Chun G.T., et al. Mechanisms underlying TGF-β1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J Leukoc Biol 81 (2007) 557-566
38. Kobayashi T., Liu X., Wen F.Q., Fang Q., Abe S., Wang X.Q., et al. Smad3 mediates TGF-beta1 induction of VEGF production in lung fibroblasts. Biochem Biophys Res Commun 327 2 (2005) 393-398
39. Fehrenbach H., Kasper M., Haase M., Schuh D., and Müller M. Differential immunolocalization of VEGF in rat and human adult lung, and in experimental rat lung fibrosis: light, fluorescence, and electron microscopy. Anat Rec 254 (1999) 61-73
40. Karmpaliotis D., Kosmidou I., Ingenito E.P., Hong K., Malhotra A., Sunday M.E., et al. Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 283 (2002) L585-L595
41. Atamas S.P., Yurovsky V.V., Wise R., Wigley F.M., Goter Robinson C.J., Henry P., et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42 (1999) 1168-1178
42. Luzina I.G., Atamas S.P., Wise R., Wigley F.M., Choi J., Xiao H.Q., et al. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum 48 (2003) 2262-2274
43. Atamas S.P., Luzina I.G., Dai H., Wilt S.G., and White B. Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 168 (2002) 1139-1145
44. empowski G.D., Chess P.R., and Phipps R.P. CD40 is a functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts. J Immunol 158 (1997) 4670-4677
45. Huaux F., Liu T., McGarry B., Ullenbruch M., Xing Z., and Phan S.H. Eosinophils and T lymphocytes possess distinct roles in bleomycin induced lung injury and fibrosis. J Immunol 171 (2003) 5470-5481
46. Hao Z., Hampel B., Yagita H., and Rajewsky K. T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis. J Exp Med 199 (2004) 1355-1365
47. Okazaki T., Nakao A., Nakano H., Takahashi F., Takahashi K., Shimozato O., et al. Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice. J Immunol 167 (2001) 1977-1981
48. Chen W.S., Kitson R.P., and Goldfarb R.H. Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1). In Vivo 16 (2002) 439-445
49. Kanazawa H., Hirata K., and Yoshikawa J. Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients. Thorax 57 (2002) 885-888
50. Piguet P.F., Collart M.A., Grau G.E., Kapanci Y., and Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 170 (1989) 655-663
51. Liu X., Kohyama T., Wang H., Zhu Y.K., Wen F.Q., Kim H.J., et al. Th2 cytokine regulation of type I collagen gel contraction mediated by human lung mesenchymal cells. Am J Physiol 282 (2002) L1049-L1056
52. Shao D.D., Suresh R., Vakil V., Gomer R.H., and Pilling D. Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 83 (2008) 1323-1333
53. Lee C.G., Link H., Baluk P., Homer R.J., Chapoval S., Bhandari V., et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 10 (2004) 1095-1103
54. Corne J., Chupp G., Lee C.G., Homer R.J., Zhu Z., Chen Q., et al. IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. J Clin Invest 106 (2000) 783-791